Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that causes inflammation and tissue damage in multiple organs of the body and requires immunosuppressants and anti-inflammatory medications for treatment. Benlysta (belimumab) is a biologic medication that targets B-lymphocyte stimulator involved in the development of autoantibodies and inflammation in SLE, and is approved for adults and children aged 5 years and above with SLE and adults with active lupus nephritis. Clinical trials have shown that belimumab significantly reduces disease activity and symptoms in patients with SLE and improves renal response in patients with lupus nephritis. Nevertheless, belimumab can cause common side effects such as infections and musculoskeletal symptoms, and may increase the risk of depression and suicide ideation in patients with psychiatric illness.